logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Michael J. Paskow

k global medical affairs, astrazeneca, gaithersburg, md, usa
H指数:11
被引数:1,339

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers

LIVER-R研究方案：一项关于 durvalumab为基础方案在肝胆肿瘤患者中的全球真实世界研究

Future Oncology
IF2.6
2025-11-240
OAAI
Masafumi Ikeda; Marcus-Alexander Wörns; Mehmet Akce; Chiun Hsu; Niall C. Tebbutt; Andrea Casadei-Gardini; Janvi Sah; Mufiza Farid-Kapadia; Heide A. Stirnadel-Farrant; Michael J. Paskow; Boris Baur; Giovanni Melillo; James Schmidt; Anna Daktera; Jennifer J. Knox
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC

HIMALAYA研究五-year总体生存率更新：曲美木单抗联合度伐利尤单抗治疗不可切除性HCC

Journal of Hepatology
IF33
2025-04-110
OAAI
Lorenza Rimassa; Stephen L. Chan; Bruno Sangro; George Lau; Masatoshi Kudo; Maria Reig; Valeriy Breder; Min-Hee Ryu; Yuriy Ostapenko; Wattana Sukeepaisarnjaroen; Maria Varela; David Tougeron; Oxana V. Crysler; Mohamed Bouattour; Tu Van Dao; Vincent C. Tam; Adilson Faccio; Junji Furuse; Long-Bin Jeng; Yoon Koo Kang; Robin K. Kelley; Michael J. Paskow; Di Ran; Ioannis Xynos; John F. Kurland; Alejandra Negro; Ghassan K. Abou-Alfa
Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

Tremelimumab (T) 联合 Durvalumab (D) 治疗不可切除性肝细胞癌（uHCC）的III期HIMALAYA研究中，基于基线肝功能的5年总生存期（OS）和总生存期（OS）。

ANNALS OF ONCOLOGY
IF65.4
2024-12-011
PRE
Kudo, M.; Rimassa, L.; Chan, S. L.; Sangro, B.; Lau, G.; Breder, V. V.; Varela, M.; Crysler, O. V.; Bouattour, M.; Dao, V. T.; Faccio, A.; Furuse, J.; Jeng, L-B.; Kang, Y-K.; Kelley, R. K.; Paskow, M. J.; Makowsky, M.; Ran, D.; Negro, A.; Abou-Alfa, G. K.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

tremelimumab联合durvalumab治疗不可切除肝细胞癌的III期喜马拉雅研究的四年总生存期更新

ANNALS OF ONCOLOGY
IF65.4
2024-05-0139
OA
Sangro, B.; Chan, S. L.; Kelley, R. K.; Lau, G.; Kudo, M.; Sukeepaisarnjaroen, W.; Yarchoan, M.; De Toni, E. N.; Furuse, J.; Kang, Y. K.; Galle, P. R.; Rimassa, L.; Heurgue, A.; Tam, V. C.; Van Dao, T.; Thungappa, S. C.; Breder, V.; Ostapenko, Y.; Reig, M.; Makowsky, M.; Paskow, M. J.; Gupta, C.; Kurland, J. F.; Negro, A.; Abou-Alfa, G. K.

研究方向

暂未获取到该数据
L
Lorenza Rimassa
H 指数:70论文数:769被引数:2.2万
A
Alejandra Negro
H 指数:19论文数:74被引数:3,675
M
Masatoshi Kudo
H 指数:143论文数:2,840被引数:12.5万
B
Bruno Sangro
H 指数:95论文数:819被引数:4.8万
J
Janvi Sah
H 指数:10论文数:54被引数:370
S
S.L. Chan
H 指数:4论文数:20被引数:215
T
Tu Van Dao
H 指数:15论文数:82被引数:2,865
J
Junji Furuse
H 指数:75论文数:731被引数:2.8万
R
Robin Kate Kelley
H 指数:94论文数:510被引数:7.9万
G
George Lau
H 指数:77论文数:333被引数:2.9万